M1 Kliniken publishes 2025 annual report

  • M1 Kliniken published its 2025 annual report, highlighting a stronger earnings profile driven by higher profitability in its core Beauty business.
  • International footprint was reshaped through the closure of six loss-making sites in the UK and Australia, while expanding in Hungary with another center in Budapest; the network ended the year with 58 sites across 10 countries.
  • Strategic focus tightened with the completion of the HAEMATO Pharm sale to PHOENIX effective Jan. 31, 2026, positioning the group as a pure-play medical aesthetics provider from 2026.
  • Cash generation improved, supporting an unchanged dividend proposal of EUR 1.2 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. M1 Kliniken AG published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.